Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Hemophilia A
Interventions
DRUG

rFVIIIFc

Administered as specified in the treatment arm.

Trial Locations (78)

1023

Research Site, Auckland

1090

Research Site, Vienna

1200

Research Site, Brussels

2050

Research Site, Camperdown

2193

Research Site, Johannesburg

3052

Research Site, Melbourne

3181

Research site, Melbourne

3200

Research site, Hamilton

4101

Research Site, South Brisbane

4410

Research Site, Palmerston North

5000

Research Site, Adelaide

6008

Research Site, Subiaco

6021

Research site, Wellington

6150

Research Site, Murdoch

7925

Research Site, Cape Town

8011

Research Site, Christchurch

8035

Research Site, Barcelona

8091

Research Site, Zurich

10249

Research Site, Berlin

15213

Research Site, Pittsburgh

19104

Research Site, Philadelphia

19107

Research Site, Philadelphia

20010

Research Site, Washington D.C.

20122

Research Site, Milan

27599

Research Site, Chapel Hill

28046

Research Site, Madrid

36100

Research Site, Vicenza

41345

Research Site, Gothenburg

45229

Research Site, Cincinnati

46260

Research Site, Indianapolis

48823

Research Site, East Lansing

50134

Research Site, Florence

52242

Research Site, Iowa City

52621

Research Site, Ramat Gan

53127

Research Site, Bonn

63104

Research Site, St Louis

69677

Research Site, Bron

70112

Research Site, New Orleans

77030

Research Site, Houston

84132

Research Site, Salt Lake City

89109

Research Site, Las Vegas

90007

Research Site, Los Angeles

90027

Research Site, Los Angeles

92123

Research Site, San Diego

92868

Research Site, Orange

95817

Research Site, Sacramento

97239

Research Site, Portland

98104

Research Site, Seattle

110002

Research Site, New Delhi

141008

Research Site, Ludhiana

411004

Research Site, Pune

560034

Research Site, Bangalore

632004

Research Site, Vellore

02115

Research Site, Boston

13083-878

Research Site, Campinas

V6Z 1Y6

Research Site, Vancouver

M5G 1X8

Research Site, Toronto

Unknown

Children Cancer Centre, Hong Kong

Sir Yue Kong Pao Center for Cancer, Hong Kong

Research Site, Hong Kong

D12 N512

Research Site, Dublin

466-8560

Research Site, Nagoya

807-8556

Research Site, Kitakyushu

216-8511

Research Site, Kawasaki

634-8522

Research Site, Kashihara-shi

160-0023

Research Site, Shinjuku-ku

167-8515

Research Site, Tokyo

9713 GZ

Research Site, Groningen

20-093

Research Site, Lublin

CB2 0QQ

Research Site, Cambridge

E1 1BB

Research Site, London

SE1 7EH

Research Site, London

Research Site, London

WC1N 3JH

Research Site, London

RG24 9NA

Research Site, Basingstoke

NW3 2QG

Research Site, Hamstead

G3 8SJ

Research Site, Glasgow

G4 0SF

Research Site, Glasgow

Sponsors
All Listed Sponsors
lead

Bioverativ Therapeutics Inc.

INDUSTRY

NCT01454739 - Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A | Biotech Hunter | Biotech Hunter